| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Yoga | 17 | 2022 | 78 | 7.780 |
Why?
|
| Acupuncture Therapy | 13 | 2022 | 89 | 5.800 |
Why?
|
| Quality of Life | 73 | 2024 | 4532 | 5.590 |
Why?
|
| Meditation | 15 | 2023 | 73 | 5.430 |
Why?
|
| Integrative Oncology | 9 | 2024 | 30 | 3.970 |
Why?
|
| Neoplasms | 58 | 2024 | 15193 | 3.630 |
Why?
|
| Stress, Psychological | 26 | 2019 | 1000 | 3.540 |
Why?
|
| Sleep Wake Disorders | 14 | 2022 | 348 | 3.280 |
Why?
|
| Caregivers | 12 | 2022 | 677 | 3.240 |
Why?
|
| Complementary Therapies | 14 | 2020 | 126 | 3.070 |
Why?
|
| Xerostomia | 7 | 2022 | 190 | 2.760 |
Why?
|
| Breast Neoplasms | 37 | 2024 | 15694 | 2.620 |
Why?
|
| Fatigue | 18 | 2023 | 1239 | 2.600 |
Why?
|
| Adaptation, Psychological | 23 | 2023 | 764 | 2.460 |
Why?
|
| Depression | 21 | 2023 | 1715 | 2.390 |
Why?
|
| Carcinoma, Renal Cell | 14 | 2022 | 2326 | 2.240 |
Why?
|
| Integrative Medicine | 8 | 2023 | 39 | 2.130 |
Why?
|
| Hot Flashes | 5 | 2020 | 37 | 2.000 |
Why?
|
| Nausea | 6 | 2023 | 525 | 1.870 |
Why?
|
| Survivors | 10 | 2023 | 1031 | 1.840 |
Why?
|
| Qigong | 3 | 2020 | 12 | 1.820 |
Why?
|
| Tai Ji | 3 | 2020 | 16 | 1.800 |
Why?
|
| Peripheral Nervous System Diseases | 4 | 2022 | 393 | 1.690 |
Why?
|
| Mindfulness | 4 | 2020 | 58 | 1.640 |
Why?
|
| Writing | 6 | 2023 | 104 | 1.530 |
Why?
|
| Anxiety | 9 | 2023 | 1179 | 1.460 |
Why?
|
| Antineoplastic Agents | 18 | 2023 | 14289 | 1.420 |
Why?
|
| Middle Aged | 106 | 2024 | 86204 | 1.330 |
Why?
|
| Kidney Neoplasms | 10 | 2022 | 3022 | 1.320 |
Why?
|
| Humans | 176 | 2024 | 261506 | 1.260 |
Why?
|
| Female | 123 | 2024 | 141928 | 1.240 |
Why?
|
| Neurofeedback | 2 | 2018 | 19 | 1.220 |
Why?
|
| Breathing Exercises | 3 | 2021 | 21 | 1.030 |
Why?
|
| Pilot Projects | 13 | 2023 | 2803 | 1.020 |
Why?
|
| Sleep | 7 | 2022 | 413 | 1.010 |
Why?
|
| Electroacupuncture | 3 | 2014 | 35 | 0.980 |
Why?
|
| Exercise | 7 | 2021 | 1183 | 0.970 |
Why?
|
| Communication | 6 | 2016 | 876 | 0.960 |
Why?
|
| Telemedicine | 3 | 2021 | 471 | 0.950 |
Why?
|
| Mind-Body Therapies | 3 | 2020 | 29 | 0.950 |
Why?
|
| Male | 96 | 2024 | 123000 | 0.940 |
Why?
|
| Waiting Lists | 5 | 2017 | 263 | 0.930 |
Why?
|
| Brain-Computer Interfaces | 1 | 2023 | 14 | 0.930 |
Why?
|
| Cross-Cultural Comparison | 3 | 2022 | 87 | 0.920 |
Why?
|
| Acupuncture | 3 | 2020 | 22 | 0.920 |
Why?
|
| Magnesium | 1 | 2024 | 160 | 0.920 |
Why?
|
| Prostatectomy | 4 | 2013 | 962 | 0.910 |
Why?
|
| Spirituality | 7 | 2020 | 129 | 0.910 |
Why?
|
| Actigraphy | 2 | 2020 | 54 | 0.900 |
Why?
|
| Adult | 75 | 2023 | 77950 | 0.900 |
Why?
|
| Hydrocortisone | 5 | 2016 | 388 | 0.900 |
Why?
|
| Aged | 71 | 2024 | 70117 | 0.880 |
Why?
|
| Life Style | 5 | 2024 | 612 | 0.840 |
Why?
|
| Massage | 2 | 2022 | 15 | 0.840 |
Why?
|
| Carcinoma | 5 | 2020 | 2578 | 0.830 |
Why?
|
| Nasopharyngeal Neoplasms | 4 | 2012 | 323 | 0.780 |
Why?
|
| Sexual Partners | 2 | 2018 | 112 | 0.760 |
Why?
|
| Affect | 6 | 2014 | 288 | 0.760 |
Why?
|
| Lung Neoplasms | 9 | 2023 | 11538 | 0.750 |
Why?
|
| Cancer Survivors | 7 | 2024 | 650 | 0.750 |
Why?
|
| Regression Analysis | 8 | 2017 | 1546 | 0.750 |
Why?
|
| Biological Products | 1 | 2024 | 274 | 0.740 |
Why?
|
| Head and Neck Neoplasms | 6 | 2022 | 3976 | 0.740 |
Why?
|
| Vomiting, Anticipatory | 1 | 2020 | 2 | 0.740 |
Why?
|
| Anorexia | 1 | 2021 | 143 | 0.740 |
Why?
|
| Electroencephalography | 3 | 2019 | 898 | 0.730 |
Why?
|
| Social Support | 11 | 2019 | 560 | 0.730 |
Why?
|
| Nursing Care | 1 | 2020 | 13 | 0.730 |
Why?
|
| Neuralgia | 1 | 2023 | 251 | 0.720 |
Why?
|
| Professional-Patient Relations | 1 | 2021 | 124 | 0.710 |
Why?
|
| Hypnosis, Anesthetic | 1 | 2019 | 6 | 0.700 |
Why?
|
| Medicine, Chinese Traditional | 6 | 2020 | 30 | 0.700 |
Why?
|
| Self Report | 6 | 2020 | 756 | 0.690 |
Why?
|
| Vomiting | 2 | 2014 | 354 | 0.690 |
Why?
|
| Physical Therapists | 1 | 2019 | 5 | 0.690 |
Why?
|
| Patient Reported Outcome Measures | 3 | 2019 | 799 | 0.680 |
Why?
|
| Pain Management | 3 | 2013 | 668 | 0.680 |
Why?
|
| Pain, Postoperative | 6 | 2010 | 610 | 0.660 |
Why?
|
| Ovarian Neoplasms | 6 | 2024 | 4638 | 0.660 |
Why?
|
| Glioma | 2 | 2022 | 1963 | 0.660 |
Why?
|
| Radiation Injuries | 2 | 2019 | 1411 | 0.650 |
Why?
|
| Feasibility Studies | 10 | 2021 | 2292 | 0.640 |
Why?
|
| Surveys and Questionnaires | 27 | 2023 | 5687 | 0.640 |
Why?
|
| Pain | 6 | 2023 | 1658 | 0.630 |
Why?
|
| Treatment Outcome | 29 | 2020 | 32848 | 0.630 |
Why?
|
| Biopsy, Large-Core Needle | 1 | 2018 | 134 | 0.620 |
Why?
|
| Prostatic Neoplasms | 8 | 2023 | 5767 | 0.610 |
Why?
|
| Spouses | 2 | 2020 | 134 | 0.610 |
Why?
|
| Medical Oncology | 9 | 2023 | 1423 | 0.610 |
Why?
|
| Morphine | 4 | 2008 | 308 | 0.600 |
Why?
|
| Emotions | 4 | 2023 | 562 | 0.590 |
Why?
|
| Analgesia, Patient-Controlled | 3 | 2008 | 59 | 0.580 |
Why?
|
| Expressed Emotion | 1 | 2016 | 22 | 0.560 |
Why?
|
| Oncology Nursing | 3 | 2013 | 51 | 0.540 |
Why?
|
| Exercise Therapy | 1 | 2019 | 288 | 0.540 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 6 | 2023 | 5319 | 0.520 |
Why?
|
| Cognition Disorders | 2 | 2013 | 786 | 0.520 |
Why?
|
| Cluster Analysis | 1 | 2017 | 1053 | 0.510 |
Why?
|
| Mastectomy, Segmental | 2 | 2019 | 1026 | 0.510 |
Why?
|
| CA-125 Antigen | 2 | 2006 | 226 | 0.500 |
Why?
|
| Arthralgia | 1 | 2014 | 89 | 0.480 |
Why?
|
| Alkaline Phosphatase | 1 | 2014 | 207 | 0.470 |
Why?
|
| Physician-Patient Relations | 5 | 2013 | 792 | 0.470 |
Why?
|
| Patient-Centered Care | 2 | 2014 | 294 | 0.460 |
Why?
|
| Antiemetics | 1 | 2014 | 125 | 0.450 |
Why?
|
| Brain | 4 | 2022 | 4113 | 0.450 |
Why?
|
| Cancer Care Facilities | 5 | 2021 | 884 | 0.450 |
Why?
|
| Bayes Theorem | 1 | 2017 | 1021 | 0.450 |
Why?
|
| Behavior Therapy | 2 | 2021 | 298 | 0.450 |
Why?
|
| Amphibian Venoms | 4 | 2015 | 12 | 0.440 |
Why?
|
| Attitude to Health | 4 | 2010 | 465 | 0.430 |
Why?
|
| Neurotransmitter Agents | 1 | 2013 | 159 | 0.420 |
Why?
|
| Hemoglobins | 1 | 2014 | 477 | 0.420 |
Why?
|
| Health Status | 3 | 2006 | 590 | 0.410 |
Why?
|
| Gynecologic Surgical Procedures | 3 | 2005 | 356 | 0.410 |
Why?
|
| Truth Disclosure | 3 | 2005 | 180 | 0.390 |
Why?
|
| Taxoids | 5 | 2017 | 967 | 0.370 |
Why?
|
| Aged, 80 and over | 21 | 2018 | 29902 | 0.370 |
Why?
|
| Preoperative Care | 5 | 2011 | 1529 | 0.360 |
Why?
|
| Mastectomy | 3 | 2010 | 1534 | 0.360 |
Why?
|
| Ileus | 1 | 2010 | 27 | 0.360 |
Why?
|
| Antibody Formation | 1 | 2011 | 383 | 0.360 |
Why?
|
| Interferon-alpha | 2 | 2011 | 889 | 0.360 |
Why?
|
| Preoperative Period | 1 | 2010 | 344 | 0.360 |
Why?
|
| Diet | 5 | 2024 | 1440 | 0.350 |
Why?
|
| Stress Disorders, Post-Traumatic | 3 | 2015 | 604 | 0.350 |
Why?
|
| Practice Guidelines as Topic | 2 | 2018 | 2403 | 0.350 |
Why?
|
| Cognitive Dysfunction | 1 | 2014 | 333 | 0.350 |
Why?
|
| Analgesics, Opioid | 4 | 2008 | 1371 | 0.350 |
Why?
|
| Young Adult | 13 | 2020 | 21445 | 0.340 |
Why?
|
| Cell Proliferation | 4 | 2019 | 7226 | 0.340 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 10 | 2020 | 15862 | 0.330 |
Why?
|
| Indoles | 1 | 2014 | 1009 | 0.330 |
Why?
|
| Radiotherapy | 3 | 2013 | 1824 | 0.320 |
Why?
|
| Carboplatin | 5 | 2024 | 823 | 0.320 |
Why?
|
| Melanoma | 5 | 2021 | 5317 | 0.320 |
Why?
|
| Colectomy | 1 | 2010 | 288 | 0.310 |
Why?
|
| Acupuncture Points | 2 | 2020 | 18 | 0.310 |
Why?
|
| Pain Measurement | 6 | 2018 | 953 | 0.310 |
Why?
|
| Cognition | 1 | 2014 | 968 | 0.310 |
Why?
|
| Cancer Vaccines | 2 | 2002 | 697 | 0.290 |
Why?
|
| Muscle Stretching Exercises | 2 | 2017 | 17 | 0.280 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2015 | 2594 | 0.280 |
Why?
|
| Tibet | 2 | 2022 | 11 | 0.280 |
Why?
|
| Health Behavior | 3 | 2017 | 603 | 0.270 |
Why?
|
| Prospective Studies | 8 | 2024 | 12873 | 0.260 |
Why?
|
| Attitude of Health Personnel | 3 | 2021 | 918 | 0.260 |
Why?
|
| Prostate-Specific Antigen | 3 | 2011 | 993 | 0.260 |
Why?
|
| China | 2 | 2017 | 606 | 0.260 |
Why?
|
| Esophageal Neoplasms | 1 | 2019 | 3168 | 0.260 |
Why?
|
| Evidence-Based Medicine | 4 | 2014 | 1085 | 0.260 |
Why?
|
| Mental Health | 6 | 2013 | 415 | 0.250 |
Why?
|
| Single-Blind Method | 2 | 2018 | 409 | 0.250 |
Why?
|
| Mass Screening | 4 | 2015 | 1509 | 0.250 |
Why?
|
| Physicians | 3 | 2020 | 882 | 0.240 |
Why?
|
| Depressive Disorder | 2 | 2014 | 557 | 0.240 |
Why?
|
| Psilocybin | 1 | 2023 | 4 | 0.240 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2010 | 1216 | 0.230 |
Why?
|
| Defense Mechanisms | 1 | 2003 | 22 | 0.230 |
Why?
|
| United States | 10 | 2024 | 15433 | 0.230 |
Why?
|
| Analgesia | 1 | 2004 | 94 | 0.230 |
Why?
|
| Sick Role | 1 | 2003 | 64 | 0.230 |
Why?
|
| Disease Management | 4 | 2019 | 1052 | 0.230 |
Why?
|
| Immunotherapy, Active | 1 | 2003 | 46 | 0.230 |
Why?
|
| Time Factors | 10 | 2020 | 12926 | 0.230 |
Why?
|
| Agaricales | 1 | 2023 | 11 | 0.230 |
Why?
|
| Laparotomy | 1 | 2004 | 211 | 0.230 |
Why?
|
| Disability Evaluation | 1 | 2004 | 249 | 0.220 |
Why?
|
| Organoplatinum Compounds | 2 | 2017 | 702 | 0.220 |
Why?
|
| Paclitaxel | 4 | 2020 | 1996 | 0.220 |
Why?
|
| Liver Neoplasms | 6 | 2022 | 4557 | 0.220 |
Why?
|
| Politics | 1 | 2023 | 74 | 0.220 |
Why?
|
| Behavioral Medicine | 1 | 2022 | 14 | 0.220 |
Why?
|
| Fluorouracil | 3 | 2017 | 1944 | 0.210 |
Why?
|
| Neoplasm Recurrence, Local | 3 | 2017 | 10035 | 0.210 |
Why?
|
| Longitudinal Studies | 3 | 2019 | 1945 | 0.200 |
Why?
|
| Moxibustion | 1 | 2021 | 9 | 0.200 |
Why?
|
| Colonic Neoplasms | 1 | 2010 | 1390 | 0.200 |
Why?
|
| Pituitary-Adrenal System | 1 | 2001 | 97 | 0.200 |
Why?
|
| Lymphoma | 2 | 2014 | 1467 | 0.200 |
Why?
|
| Texas | 8 | 2021 | 6311 | 0.200 |
Why?
|
| Dietary Fiber | 1 | 2021 | 123 | 0.200 |
Why?
|
| Bufanolides | 2 | 2011 | 19 | 0.200 |
Why?
|
| Hypothalamo-Hypophyseal System | 1 | 2001 | 127 | 0.200 |
Why?
|
| Nurse-Patient Relations | 2 | 2016 | 23 | 0.200 |
Why?
|
| Heat-Shock Proteins | 1 | 2002 | 311 | 0.190 |
Why?
|
| Music Therapy | 1 | 2021 | 17 | 0.190 |
Why?
|
| Magnesium Deficiency | 1 | 2020 | 21 | 0.190 |
Why?
|
| Remote Consultation | 1 | 2021 | 37 | 0.190 |
Why?
|
| Videoconferencing | 1 | 2021 | 56 | 0.190 |
Why?
|
| Tumor Microenvironment | 3 | 2022 | 2864 | 0.190 |
Why?
|
| Skin Neoplasms | 3 | 2003 | 4654 | 0.180 |
Why?
|
| Social Adjustment | 2 | 2019 | 114 | 0.180 |
Why?
|
| Health Personnel | 2 | 2021 | 625 | 0.180 |
Why?
|
| Personal Satisfaction | 1 | 2021 | 140 | 0.180 |
Why?
|
| Pancreatic Neoplasms | 3 | 2012 | 5061 | 0.180 |
Why?
|
| Conditioning, Classical | 1 | 2020 | 69 | 0.180 |
Why?
|
| Neoplasm Staging | 6 | 2020 | 13658 | 0.180 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2010 | 1209 | 0.180 |
Why?
|
| Renal Tubular Transport, Inborn Errors | 1 | 2019 | 11 | 0.170 |
Why?
|
| Hypercalciuria | 1 | 2019 | 14 | 0.170 |
Why?
|
| Nephrocalcinosis | 1 | 2019 | 17 | 0.170 |
Why?
|
| Osteoradionecrosis | 1 | 2020 | 123 | 0.170 |
Why?
|
| Cyclophosphamide | 3 | 2017 | 3001 | 0.170 |
Why?
|
| Doxorubicin | 3 | 2017 | 3005 | 0.170 |
Why?
|
| Panax | 2 | 2017 | 33 | 0.170 |
Why?
|
| Qualitative Research | 3 | 2017 | 556 | 0.170 |
Why?
|
| Probiotics | 1 | 2021 | 228 | 0.170 |
Why?
|
| Counseling | 2 | 2019 | 381 | 0.170 |
Why?
|
| A549 Cells | 1 | 2019 | 124 | 0.170 |
Why?
|
| Anti-Anxiety Agents | 1 | 2019 | 90 | 0.160 |
Why?
|
| Neoplasm Metastasis | 5 | 2017 | 5112 | 0.160 |
Why?
|
| Preliminary Data | 1 | 2018 | 12 | 0.160 |
Why?
|
| Effect Modifier, Epidemiologic | 1 | 2017 | 21 | 0.160 |
Why?
|
| Cytokines | 3 | 2019 | 2809 | 0.160 |
Why?
|
| Acetaminophen | 1 | 2019 | 116 | 0.160 |
Why?
|
| Patient Satisfaction | 4 | 2013 | 915 | 0.160 |
Why?
|
| Lung | 2 | 2020 | 3151 | 0.160 |
Why?
|
| Students | 1 | 2000 | 324 | 0.160 |
Why?
|
| Terminal Care | 1 | 2023 | 447 | 0.160 |
Why?
|
| Patient Education as Topic | 4 | 2016 | 748 | 0.160 |
Why?
|
| Cross-Sectional Studies | 4 | 2024 | 4314 | 0.160 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2019 | 126 | 0.150 |
Why?
|
| Monitoring, Intraoperative | 1 | 2019 | 264 | 0.150 |
Why?
|
| Oncologists | 1 | 2020 | 134 | 0.150 |
Why?
|
| Causality | 1 | 2017 | 178 | 0.150 |
Why?
|
| Musculoskeletal Manipulations | 1 | 2017 | 12 | 0.150 |
Why?
|
| Epirubicin | 1 | 2017 | 157 | 0.150 |
Why?
|
| Patient Participation | 1 | 2001 | 446 | 0.150 |
Why?
|
| Follow-Up Studies | 9 | 2019 | 14889 | 0.150 |
Why?
|
| Platinum Compounds | 1 | 2017 | 131 | 0.150 |
Why?
|
| Education, Medical | 1 | 2000 | 331 | 0.140 |
Why?
|
| Religion | 2 | 2020 | 91 | 0.140 |
Why?
|
| Neuropsychological Tests | 2 | 2013 | 1178 | 0.140 |
Why?
|
| Arachidonate 12-Lipoxygenase | 1 | 2016 | 17 | 0.140 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2014 | 2341 | 0.140 |
Why?
|
| Perception | 1 | 2018 | 350 | 0.140 |
Why?
|
| Depressive Disorder, Major | 1 | 2001 | 441 | 0.140 |
Why?
|
| Dietary Sucrose | 1 | 2016 | 42 | 0.140 |
Why?
|
| Sentinel Lymph Node Biopsy | 2 | 2019 | 1415 | 0.130 |
Why?
|
| Health Education | 1 | 1998 | 309 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2015 | 4938 | 0.130 |
Why?
|
| Referral and Consultation | 3 | 2022 | 899 | 0.130 |
Why?
|
| Cisplatin | 3 | 2020 | 2432 | 0.130 |
Why?
|
| Signal Transduction | 2 | 2016 | 11965 | 0.130 |
Why?
|
| Heel | 1 | 2014 | 10 | 0.130 |
Why?
|
| Drugs, Chinese Herbal | 2 | 2015 | 48 | 0.130 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2019 | 486 | 0.130 |
Why?
|
| Disease-Free Survival | 5 | 2016 | 10001 | 0.120 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2017 | 3890 | 0.120 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2020 | 992 | 0.120 |
Why?
|
| Dyssomnias | 1 | 2014 | 7 | 0.120 |
Why?
|
| Cost of Illness | 1 | 2018 | 498 | 0.120 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2019 | 673 | 0.120 |
Why?
|
| Inpatients | 1 | 2020 | 678 | 0.120 |
Why?
|
| Telomere Shortening | 1 | 2014 | 56 | 0.120 |
Why?
|
| Data Collection | 2 | 2014 | 620 | 0.120 |
Why?
|
| Prognosis | 7 | 2020 | 21713 | 0.120 |
Why?
|
| Caspase 3 | 1 | 2015 | 471 | 0.120 |
Why?
|
| Carcinoma, Hepatocellular | 3 | 2011 | 2027 | 0.120 |
Why?
|
| Combined Modality Therapy | 5 | 2017 | 8865 | 0.120 |
Why?
|
| Retinoblastoma Protein | 1 | 2015 | 335 | 0.120 |
Why?
|
| Lung Transplantation | 1 | 1998 | 359 | 0.120 |
Why?
|
| Serum Albumin | 1 | 2014 | 257 | 0.120 |
Why?
|
| Adenocarcinoma | 1 | 2012 | 7789 | 0.120 |
Why?
|
| Computers, Handheld | 1 | 2014 | 69 | 0.120 |
Why?
|
| Neurosurgical Procedures | 1 | 2018 | 609 | 0.110 |
Why?
|
| Music | 1 | 2013 | 36 | 0.110 |
Why?
|
| Psychotherapy | 2 | 2023 | 247 | 0.110 |
Why?
|
| Plant Extracts | 1 | 2015 | 215 | 0.110 |
Why?
|
| Intestinal Pseudo-Obstruction | 1 | 2013 | 39 | 0.110 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2021 | 907 | 0.110 |
Why?
|
| Saliva | 1 | 2014 | 231 | 0.110 |
Why?
|
| Electrophysiological Phenomena | 1 | 2013 | 75 | 0.110 |
Why?
|
| Anura | 1 | 2012 | 11 | 0.110 |
Why?
|
| DNA Repair | 1 | 2000 | 1872 | 0.110 |
Why?
|
| Patient Compliance | 2 | 2016 | 667 | 0.110 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2015 | 639 | 0.110 |
Why?
|
| Macrophages | 1 | 2019 | 1304 | 0.110 |
Why?
|
| Salivation | 1 | 2012 | 20 | 0.110 |
Why?
|
| Computer Simulation | 1 | 2017 | 1529 | 0.110 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2020 | 573 | 0.110 |
Why?
|
| Killer Cells, Natural | 2 | 2011 | 904 | 0.110 |
Why?
|
| Mammary Glands, Animal | 1 | 2016 | 533 | 0.100 |
Why?
|
| Brain Neoplasms | 2 | 2020 | 4849 | 0.100 |
Why?
|
| Societies, Medical | 1 | 2018 | 1335 | 0.100 |
Why?
|
| Risk Factors | 6 | 2017 | 17523 | 0.100 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 2012 | 70 | 0.100 |
Why?
|
| Mood Disorders | 1 | 2013 | 163 | 0.100 |
Why?
|
| Mice, Inbred C57BL | 2 | 2021 | 6942 | 0.100 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2017 | 600 | 0.100 |
Why?
|
| Hyperalgesia | 2 | 2004 | 238 | 0.100 |
Why?
|
| Chemoradiotherapy | 1 | 2020 | 1946 | 0.100 |
Why?
|
| Retrospective Studies | 9 | 2023 | 37905 | 0.100 |
Why?
|
| Fear | 2 | 2023 | 254 | 0.100 |
Why?
|
| Mice | 4 | 2021 | 34495 | 0.100 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2012 | 129 | 0.100 |
Why?
|
| Animals | 6 | 2021 | 59536 | 0.100 |
Why?
|
| Gene Expression Regulation, Enzymologic | 2 | 2011 | 703 | 0.100 |
Why?
|
| Observer Variation | 1 | 2013 | 671 | 0.100 |
Why?
|
| Reinforcement Schedule | 1 | 1990 | 26 | 0.100 |
Why?
|
| Clinical Trials as Topic | 1 | 2021 | 3719 | 0.100 |
Why?
|
| Appetitive Behavior | 1 | 1990 | 18 | 0.090 |
Why?
|
| Recombinant Proteins | 3 | 2011 | 2927 | 0.090 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2015 | 852 | 0.090 |
Why?
|
| Memory | 2 | 1993 | 429 | 0.090 |
Why?
|
| Neuronal Plasticity | 1 | 2013 | 304 | 0.090 |
Why?
|
| Association Learning | 1 | 1990 | 28 | 0.090 |
Why?
|
| Homeopathy | 1 | 2010 | 9 | 0.090 |
Why?
|
| Pyridines | 2 | 2022 | 1244 | 0.090 |
Why?
|
| Remission, Spontaneous | 1 | 2010 | 119 | 0.090 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2013 | 901 | 0.090 |
Why?
|
| Benzenesulfonates | 1 | 2011 | 195 | 0.090 |
Why?
|
| Sodium-Potassium-Exchanging ATPase | 1 | 2010 | 132 | 0.090 |
Why?
|
| Genital Neoplasms, Female | 1 | 2017 | 735 | 0.090 |
Why?
|
| Defecation | 1 | 2010 | 58 | 0.090 |
Why?
|
| Comprehensive Health Care | 1 | 2010 | 49 | 0.090 |
Why?
|
| Postoperative Nausea and Vomiting | 1 | 2010 | 51 | 0.090 |
Why?
|
| Life Change Events | 2 | 2004 | 83 | 0.090 |
Why?
|
| Gastrointestinal Motility | 1 | 2010 | 92 | 0.090 |
Why?
|
| Standard of Care | 1 | 2011 | 243 | 0.090 |
Why?
|
| Urologic Neoplasms | 1 | 2011 | 188 | 0.090 |
Why?
|
| Carcinogenesis | 1 | 2016 | 1026 | 0.090 |
Why?
|
| Mental Recall | 1 | 1990 | 171 | 0.090 |
Why?
|
| Sensitivity and Specificity | 2 | 2015 | 4971 | 0.090 |
Why?
|
| Phytotherapy | 1 | 2010 | 110 | 0.090 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2011 | 363 | 0.080 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2015 | 1039 | 0.080 |
Why?
|
| Postoperative Period | 1 | 2011 | 665 | 0.080 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2011 | 665 | 0.080 |
Why?
|
| Survival Rate | 4 | 2019 | 12221 | 0.080 |
Why?
|
| Decision Making | 2 | 2010 | 1287 | 0.080 |
Why?
|
| Comorbidity | 1 | 2015 | 2352 | 0.080 |
Why?
|
| Ethanol | 1 | 1990 | 264 | 0.080 |
Why?
|
| Risk Assessment | 2 | 2017 | 6869 | 0.080 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 2010 | 134 | 0.080 |
Why?
|
| Focus Groups | 1 | 2008 | 256 | 0.080 |
Why?
|
| Cohort Studies | 3 | 2021 | 9244 | 0.080 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2009 | 153 | 0.080 |
Why?
|
| Tongue Neoplasms | 1 | 2009 | 246 | 0.080 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2007 | 104 | 0.080 |
Why?
|
| Glioblastoma | 1 | 2018 | 1797 | 0.080 |
Why?
|
| Double-Blind Method | 3 | 2017 | 2588 | 0.080 |
Why?
|
| Survival Analysis | 2 | 2014 | 9180 | 0.070 |
Why?
|
| Lidocaine | 2 | 2004 | 76 | 0.070 |
Why?
|
| Multivariate Analysis | 4 | 2012 | 4298 | 0.070 |
Why?
|
| Prevalence | 1 | 2015 | 3260 | 0.070 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2008 | 220 | 0.070 |
Why?
|
| Learning | 1 | 1990 | 403 | 0.070 |
Why?
|
| Age Factors | 3 | 2012 | 5377 | 0.070 |
Why?
|
| Deoxycytidine | 1 | 2012 | 1353 | 0.070 |
Why?
|
| Men | 1 | 2006 | 9 | 0.070 |
Why?
|
| Treatment Failure | 1 | 2010 | 1391 | 0.070 |
Why?
|
| Recovery of Function | 1 | 2010 | 703 | 0.070 |
Why?
|
| Fentanyl | 2 | 2004 | 148 | 0.070 |
Why?
|
| Anesthetics, Local | 2 | 2004 | 163 | 0.070 |
Why?
|
| Program Evaluation | 2 | 2008 | 597 | 0.070 |
Why?
|
| Patients | 1 | 2008 | 245 | 0.070 |
Why?
|
| Biomarkers | 2 | 2014 | 5047 | 0.070 |
Why?
|
| Disease Progression | 2 | 2023 | 6682 | 0.070 |
Why?
|
| Drug Administration Schedule | 1 | 2011 | 3472 | 0.070 |
Why?
|
| Neoadjuvant Therapy | 2 | 2017 | 4975 | 0.070 |
Why?
|
| Quality of Health Care | 1 | 2010 | 621 | 0.060 |
Why?
|
| Infusions, Intravenous | 1 | 2008 | 1382 | 0.060 |
Why?
|
| Community Health Services | 1 | 2006 | 126 | 0.060 |
Why?
|
| Clinical Competence | 2 | 2010 | 1270 | 0.060 |
Why?
|
| Transcription, Genetic | 1 | 2012 | 3154 | 0.060 |
Why?
|
| Genome, Human | 1 | 2012 | 1869 | 0.060 |
Why?
|
| Trametes | 1 | 2023 | 4 | 0.060 |
Why?
|
| Thinking | 1 | 2003 | 33 | 0.060 |
Why?
|
| Sampling Studies | 1 | 2003 | 170 | 0.060 |
Why?
|
| Avoidance Learning | 1 | 2003 | 94 | 0.060 |
Why?
|
| Postoperative Complications | 1 | 2018 | 5542 | 0.060 |
Why?
|
| Psychology | 1 | 2003 | 86 | 0.060 |
Why?
|
| Patient Care Team | 1 | 2008 | 795 | 0.060 |
Why?
|
| Personality Inventory | 1 | 2003 | 178 | 0.050 |
Why?
|
| Multiple Myeloma | 1 | 2014 | 2138 | 0.050 |
Why?
|
| Anesthesia, General | 1 | 2004 | 239 | 0.050 |
Why?
|
| Inflammation | 1 | 2012 | 2522 | 0.050 |
Why?
|
| Nurses | 1 | 2003 | 80 | 0.050 |
Why?
|
| Analgesia, Epidural | 1 | 2003 | 102 | 0.050 |
Why?
|
| Peritoneal Neoplasms | 1 | 2009 | 821 | 0.050 |
Why?
|
| Fatty Acids, Volatile | 1 | 2021 | 52 | 0.050 |
Why?
|
| Test Anxiety Scale | 1 | 2001 | 4 | 0.050 |
Why?
|
| Biomarkers, Tumor | 2 | 2019 | 10331 | 0.050 |
Why?
|
| Demography | 1 | 2003 | 435 | 0.050 |
Why?
|
| Therapeutics | 1 | 2001 | 34 | 0.050 |
Why?
|
| Temperament | 1 | 2001 | 21 | 0.050 |
Why?
|
| Employment | 1 | 2002 | 129 | 0.050 |
Why?
|
| Fecal Microbiota Transplantation | 1 | 2021 | 149 | 0.050 |
Why?
|
| Fellowships and Scholarships | 1 | 2005 | 390 | 0.050 |
Why?
|
| Genes, cdc | 1 | 2000 | 81 | 0.050 |
Why?
|
| Erectile Dysfunction | 2 | 2013 | 212 | 0.050 |
Why?
|
| Symptom Assessment | 1 | 2023 | 267 | 0.050 |
Why?
|
| Educational Status | 1 | 2002 | 397 | 0.050 |
Why?
|
| Cell Line, Tumor | 5 | 2016 | 14551 | 0.050 |
Why?
|
| Accelerometry | 1 | 2020 | 63 | 0.050 |
Why?
|
| Residence Characteristics | 1 | 2003 | 348 | 0.050 |
Why?
|
| Psychosocial Support Systems | 1 | 2020 | 7 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2020 | 4320 | 0.050 |
Why?
|
| Factor Analysis, Statistical | 1 | 2001 | 356 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2012 | 5159 | 0.050 |
Why?
|
| Anilides | 1 | 2022 | 268 | 0.050 |
Why?
|
| Religion and Medicine | 1 | 2020 | 50 | 0.040 |
Why?
|
| Syndrome | 1 | 2023 | 1351 | 0.040 |
Why?
|
| Incidence | 2 | 2020 | 5673 | 0.040 |
Why?
|
| Mammaplasty | 1 | 2007 | 780 | 0.040 |
Why?
|
| Video Recording | 1 | 2021 | 267 | 0.040 |
Why?
|
| Melanoma, Experimental | 1 | 2021 | 368 | 0.040 |
Why?
|
| Medicare | 1 | 2024 | 860 | 0.040 |
Why?
|
| Analysis of Variance | 1 | 2003 | 2307 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2023 | 6009 | 0.040 |
Why?
|
| Empathy | 1 | 2020 | 101 | 0.040 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2022 | 1248 | 0.040 |
Why?
|
| Immunotherapy | 2 | 2021 | 3341 | 0.040 |
Why?
|
| DNA Damage | 2 | 2011 | 1954 | 0.040 |
Why?
|
| Psychometrics | 1 | 2023 | 937 | 0.040 |
Why?
|
| Needs Assessment | 1 | 2020 | 233 | 0.040 |
Why?
|
| Nephrectomy | 1 | 2003 | 779 | 0.040 |
Why?
|
| Testosterone | 1 | 2023 | 619 | 0.040 |
Why?
|
| Feces | 1 | 2021 | 770 | 0.040 |
Why?
|
| Educational Measurement | 1 | 2000 | 362 | 0.040 |
Why?
|
| Motivation | 1 | 2001 | 499 | 0.040 |
Why?
|
| Prostate | 1 | 2023 | 1088 | 0.040 |
Why?
|
| Cyclonic Storms | 1 | 2019 | 88 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2003 | 1467 | 0.040 |
Why?
|
| Psychological Tests | 1 | 1998 | 131 | 0.040 |
Why?
|
| Morbidity | 1 | 2018 | 397 | 0.040 |
Why?
|
| Colorectal Neoplasms | 1 | 2012 | 3578 | 0.040 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2010 | 5178 | 0.040 |
Why?
|
| DNA Replication | 1 | 2000 | 744 | 0.040 |
Why?
|
| Transfection | 1 | 2000 | 2944 | 0.030 |
Why?
|
| Bone Neoplasms | 1 | 2007 | 2576 | 0.030 |
Why?
|
| Pandemics | 1 | 2024 | 1559 | 0.030 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2015 | 202 | 0.030 |
Why?
|
| Blotting, Western | 2 | 2011 | 3536 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2019 | 1742 | 0.030 |
Why?
|
| Random Allocation | 1 | 2016 | 703 | 0.030 |
Why?
|
| Population Surveillance | 1 | 1998 | 627 | 0.030 |
Why?
|
| Health Promotion | 1 | 1998 | 502 | 0.030 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2009 | 5437 | 0.030 |
Why?
|
| Heterografts | 1 | 2016 | 733 | 0.030 |
Why?
|
| Neoplasms, Second Primary | 1 | 2001 | 1350 | 0.030 |
Why?
|
| Adolescent | 4 | 2020 | 31252 | 0.030 |
Why?
|
| Mammary Neoplasms, Experimental | 1 | 2016 | 494 | 0.030 |
Why?
|
| Bortezomib | 1 | 2014 | 543 | 0.030 |
Why?
|
| Boronic Acids | 1 | 2014 | 362 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2013 | 543 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2002 | 1362 | 0.030 |
Why?
|
| Cardiac Glycosides | 1 | 2011 | 16 | 0.030 |
Why?
|
| Cause of Death | 1 | 2014 | 752 | 0.030 |
Why?
|
| Palliative Care | 1 | 2023 | 2037 | 0.020 |
Why?
|
| Chromones | 1 | 2011 | 120 | 0.020 |
Why?
|
| Taiwan | 1 | 2011 | 93 | 0.020 |
Why?
|
| Pyrazines | 1 | 2014 | 495 | 0.020 |
Why?
|
| Lymph Node Excision | 1 | 1999 | 1959 | 0.020 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2011 | 252 | 0.020 |
Why?
|
| Tape Recording | 1 | 2010 | 14 | 0.020 |
Why?
|
| Hep G2 Cells | 1 | 2010 | 155 | 0.020 |
Why?
|
| Thalidomide | 1 | 2014 | 569 | 0.020 |
Why?
|
| Israel | 1 | 2010 | 53 | 0.020 |
Why?
|
| Interferon-gamma | 2 | 2009 | 1144 | 0.020 |
Why?
|
| Phytolacca | 1 | 2010 | 3 | 0.020 |
Why?
|
| Thuja | 1 | 2010 | 3 | 0.020 |
Why?
|
| Conium | 1 | 2010 | 3 | 0.020 |
Why?
|
| Rats, Inbred Strains | 1 | 1990 | 410 | 0.020 |
Why?
|
| Injections, Intraperitoneal | 1 | 1990 | 197 | 0.020 |
Why?
|
| CA-19-9 Antigen | 1 | 2011 | 144 | 0.020 |
Why?
|
| Narration | 1 | 2010 | 42 | 0.020 |
Why?
|
| Morpholines | 1 | 2011 | 289 | 0.020 |
Why?
|
| Niacinamide | 1 | 2011 | 421 | 0.020 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2011 | 181 | 0.020 |
Why?
|
| India | 1 | 2010 | 301 | 0.020 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2009 | 84 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2010 | 503 | 0.020 |
Why?
|
| Blood Platelets | 1 | 1994 | 731 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2021 | 3869 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2010 | 548 | 0.020 |
Why?
|
| Apoptosis | 2 | 2015 | 7591 | 0.020 |
Why?
|
| Heart Failure | 1 | 2002 | 2516 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2011 | 1313 | 0.020 |
Why?
|
| Cell Separation | 1 | 2010 | 612 | 0.020 |
Why?
|
| Phenylurea Compounds | 1 | 2011 | 580 | 0.020 |
Why?
|
| Castration | 1 | 2007 | 122 | 0.020 |
Why?
|
| Hospitalization | 1 | 2017 | 2083 | 0.020 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2009 | 408 | 0.020 |
Why?
|
| Psychophysiology | 1 | 2007 | 16 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2015 | 8873 | 0.020 |
Why?
|
| Sex Factors | 1 | 2012 | 2139 | 0.020 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2007 | 153 | 0.020 |
Why?
|
| Axilla | 2 | 2000 | 902 | 0.020 |
Why?
|
| Placebos | 1 | 2007 | 437 | 0.020 |
Why?
|
| Telomere | 1 | 2010 | 505 | 0.020 |
Why?
|
| Digital Rectal Examination | 1 | 2006 | 14 | 0.020 |
Why?
|
| Body Image | 1 | 2007 | 141 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2011 | 1910 | 0.020 |
Why?
|
| Patient Simulation | 1 | 2005 | 40 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2010 | 2216 | 0.020 |
Why?
|
| Problem-Based Learning | 1 | 2005 | 78 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2010 | 2232 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2006 | 250 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2010 | 2084 | 0.010 |
Why?
|
| Databases, Factual | 1 | 2011 | 2218 | 0.010 |
Why?
|
| Histones | 1 | 2011 | 1466 | 0.010 |
Why?
|
| Cell Survival | 1 | 2010 | 3045 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2010 | 3033 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2010 | 5395 | 0.010 |
Why?
|
| Imatinib Mesylate | 1 | 2007 | 1665 | 0.010 |
Why?
|
| Intraoperative Period | 1 | 2003 | 246 | 0.010 |
Why?
|
| Education, Nursing | 1 | 2003 | 18 | 0.010 |
Why?
|
| Pain Threshold | 1 | 2003 | 130 | 0.010 |
Why?
|
| Mental Disorders | 1 | 2010 | 862 | 0.010 |
Why?
|
| Physician's Role | 1 | 2005 | 238 | 0.010 |
Why?
|
| Dietary Supplements | 1 | 2007 | 558 | 0.010 |
Why?
|
| Benzamides | 1 | 2007 | 1832 | 0.010 |
Why?
|
| Faculty, Medical | 1 | 2005 | 289 | 0.010 |
Why?
|
| Radiotherapy Dosage | 1 | 2009 | 3842 | 0.010 |
Why?
|
| Gene Expression | 1 | 2010 | 3570 | 0.010 |
Why?
|
| Rats | 1 | 1990 | 6086 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2011 | 6100 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2015 | 4757 | 0.010 |
Why?
|
| Phytohemagglutinins | 1 | 1998 | 71 | 0.010 |
Why?
|
| Mitogens | 1 | 1998 | 75 | 0.010 |
Why?
|
| Piperazines | 1 | 2007 | 2101 | 0.010 |
Why?
|
| Physical Fitness | 1 | 1998 | 122 | 0.010 |
Why?
|
| Shoulder Joint | 1 | 1999 | 82 | 0.010 |
Why?
|
| Range of Motion, Articular | 1 | 1999 | 144 | 0.010 |
Why?
|
| Tamoxifen | 1 | 2000 | 876 | 0.010 |
Why?
|
| Biopsy, Needle | 1 | 2000 | 1363 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 1998 | 478 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1998 | 1489 | 0.010 |
Why?
|
| Pyrimidines | 1 | 2007 | 3518 | 0.010 |
Why?
|
| Catecholamines | 1 | 1994 | 101 | 0.010 |
Why?
|
| Nuclear Reactors | 1 | 1993 | 8 | 0.010 |
Why?
|
| Students, Medical | 1 | 1998 | 399 | 0.010 |
Why?
|
| Photic Stimulation | 1 | 1994 | 259 | 0.010 |
Why?
|
| Models, Psychological | 1 | 1993 | 170 | 0.010 |
Why?
|
| Disasters | 1 | 1993 | 107 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2000 | 4892 | 0.010 |
Why?
|
| Lymphatic Metastasis | 1 | 2000 | 4844 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2000 | 2967 | 0.010 |
Why?
|
| Hemodynamics | 1 | 1994 | 935 | 0.010 |
Why?
|
| Chronic Disease | 1 | 1993 | 1819 | 0.000 |
Why?
|